Colorcon opens in Australia to meet growing demand from local pharma industry
Customers in the region will have the opportunity to conduct laboratory-scale compression and coating trials, using automated coating equipment.
Colorcon, a developer and supplier of film coating systems and excipients, has opened a new technical center in Melbourne, Australia.
The facility, which is in the award-winning Caribbean Business Park, provides customers in Australasia access to pharmaceutical class development services such as tablet formulation and coating as the region seeks to shorten supply chains and increase the capacity of its pharmaceutical sector.
Even before COVID-19, the pharmaceutical and wellness markets in Australasia were expanding led by a steady increase in the older population and strong demand for the nutritional domestic and export markets.
The new technical service center will provide both large and small customers the opportunity to work directly with Colorcon and "for the first time in Australia" conduct laboratory-scale compression and coating trials, using automated coating equipment, thereby saving development time and cost.
Glenn Russell, Technical Director, said: the facility will also "provide the opportunity to extend the educational events offered through the Colorcon Academy to our customers, with resources to conduct training programs to expand their knowledge in formulation and coating; benefiting both companies and individuals".
This new facility brings the total number of Technical Service Laboratories around the world to 22 and is the seventh within Southeast Asia.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.